Oncology Institute Inc

TOI is entrenched in a Stage 4 decline within a longer-term uptrend, having broken key multi-month support and triggering active bearish patterns. Price remains below the declining 9- and 21-EMAs with no sign of repair, confirming medium-term bearish control. Short-term conditions are unfavorable for longs, and any minor retracement toward the falling EMAs is likely resistance. Execution favors immediate participation in the breakdown continuation.

• ↑Q1 revenue $147M, up 41% YoY, fueled by pharmacy growth.
• ↑Specialty pharmacy revenue $87.5M, +77.6% YoY, diversifying income.
• ↓Earnings yield -0.97 indicates difficulty converting revenue to profit.